Results 161 to 170 of about 4,101 (234)

P065 | Clinical and genomic patterns of disease progression in cll patients treated with fixed-duration versus continuous targeted therapies

Haematologica
Introduction. Bruton tyrosine kinase inhibitors (BTKi) and venetoclax (VEN) display their effects on distinct subpopulations of chronic lymphocytic leukemia (CLL) cells: BTKi primarily target proliferating nodal cells, which are killed after mobilization
Andrea Serafin
doaj  

Refining prognostic tools in Waldenström macroglobulinemia. [PDF]

Blood Adv
Lionel AC, Thomas SK.
europepmc   +1 more source

Systemic high-dose MTX and BTK inhibitors in vitreoretinal lymphoma: efficacy and survival analysis. [PDF]

Blood Sci
Gao J, Lv LW, Zhou SW, Yao N, Yang L, Ye J, Zhang L, Peng X, Wang L.   +8 more
europepmc   +1 more source

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)

, 2023
Xiaoyu Feng, Yangyang Wang, Tao Long, Lanyue Bai, Xiaojiao Yang, Ailing Yang, Xiangmei Chen, Óscar Puig, Yangbo Yue, Zhirong Shen   +9 more
openalex   +1 more source

Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma. [PDF]

Blood Cancer J
Pfitzer J, Chakravarti S, Mazumder S, Li F, Mukherjee UK, Mitra AK.   +5 more
europepmc   +1 more source

A Retrospective Cohort Study to Assess and Compare Treatment Patterns and Healthcare Utilization for Patients with Mantle Cell Lymphoma in the Veterans Affairs System (MCLOVA) Who Were Prescribed Bruton Tyrosine Kinase Inhibitors (BTKi) [PDF]

Henry Ogbeifun, Supreet Kaur, Zohra Nooruddin, Cynthia I Nguyen, Corbyn M. Gilmore, Adriana Vargus, Kathleen Franklin, Xavier Jones, Christopher R. Frei   +8 more
openalex   +1 more source

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. [PDF]

Biomolecules
Duminuco A, De Luca P, Stanzione G, Caruso LA, Lavenia G, Scarso S, Garibaldi B, Palumbo FE, Vetro C, Palumbo GA.   +9 more
europepmc   +1 more source

Lymphotoxin-dependent elevated meningeal CXCL13:BAFF ratios drive gray matter injury. [PDF]

Nat Immunol
Naouar I, Pangan A, Zuo M, Raza SA, Champagne-Jorgensen K, Patel J, Wang A, Pu A, Ward L, Ahn JSY, Sayeed FN, Zhu J, Pössnecker E, Spring S, Sled JG, Cenni B, Nuesslein-Hildesheim B, Browning JL, Pröbstel AK, Reich DS, Gommerman JL, Ramaglia V.   +21 more
europepmc   +1 more source

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies [PDF]

Taral Patel, Rushir J. Choksi, Tejvir Singh, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Fred J. Kudrik, Gelareh Rahimighazikalayeh, Gino Cioffi, Don Parris, Anna Rui, Mike Gart, Lisa Kunst, Lindsay Aton, Poras Davé, Doug Kanovsky, J. Oliver Donegan, Lisa Morere, Jeffrey Scott, Jing‐Zhou Hou   +19 more
openalex   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source